Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) [lonafarnib] and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997

Trial Profile

Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) [lonafarnib] and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2012

At a glance

  • Drugs Lonafarnib (Primary) ; Gemcitabine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top